Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...
Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...
Biogen remains focused on advancing its immunology and rare disease pipeline, including three Phase 3 trials for Felzartamab in 2025. Q4 non-GAAP diluted EPS was $3.44 compared to analysts ...
Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...
"I am pleased to see Biogen enroll the first patient in the Phase 3 TRANSCEND study of felzartamab in AMR and look forward to the trial’s continued enrollment.” TRANSCEND is a two-part ...
Biogen's development organization had another ... is only the third agent with a positive global Phase III study in SLE. Additionally, Felzartamab was granted orphan drug designation in the ...